Добірка наукової літератури з теми "Peptide loading"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Peptide loading".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Peptide loading"
Liu, Bai, Lijing You, Kaiping Han, Hyung-il Lee, Peter Rhode, Sarah Henrickson, Ulrich H. von Andrian, and Hing C. Wong. "Peptide-loading enhancement for antigen presenting cells (93.6)." Journal of Immunology 178, no. 1_Supplement (April 1, 2007): S167. http://dx.doi.org/10.4049/jimmunol.178.supp.93.6.
Повний текст джерелаZernich, Danielle, Anthony W. Purcell, Whitney A. Macdonald, Lars Kjer-Nielsen, Lauren K. Ely, Nihay Laham, Tanya Crockford, et al. "Natural HLA Class I Polymorphism Controls the Pathway of Antigen Presentation and Susceptibility to Viral Evasion." Journal of Experimental Medicine 200, no. 1 (June 28, 2004): 13–24. http://dx.doi.org/10.1084/jem.20031680.
Повний текст джерелаMorozov, Giora I., Huaying Zhao, Michael G. Mage, Lisa F. Boyd, Jiansheng Jiang, Michael A. Dolan, Ramesh Venna, et al. "Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing." Proceedings of the National Academy of Sciences 113, no. 8 (February 11, 2016): E1006—E1015. http://dx.doi.org/10.1073/pnas.1519894113.
Повний текст джерелаVatner, Ralph Eric, and Pramod K. Srivastava. "The TCP-1 Ring Complex (TRiC) binds antigenic peptides and facilitates their cross-presentation by APCs (93.5)." Journal of Immunology 178, no. 1_Supplement (April 1, 2007): S166. http://dx.doi.org/10.4049/jimmunol.178.supp.93.5.
Повний текст джерелаHafstrand, Ida, Ece Canan Sayitoglu, Anca Apavaloaei, Benjamin John Josey, Renhua Sun, Xiao Han, Sara Pellegrino, et al. "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin." Proceedings of the National Academy of Sciences 116, no. 11 (February 26, 2019): 5055–60. http://dx.doi.org/10.1073/pnas.1807656116.
Повний текст джерелаBadrinath, Soumya, Heike Kunze-Schumacher, Rainer Blasczyk, Trevor Huyton, and Christina Bade-Doeding. "A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A*24 Allotypes." Journal of Immunology Research 2014 (2014): 1–12. http://dx.doi.org/10.1155/2014/298145.
Повний текст джерелаYuan, Xin, Yingzhou Qin, Qingmei Tian, Cuijuan Liu, Xiangzhou Meng, Bo Qie, Fan Gao, et al. "Smart delivery of poly-peptide composite for effective cancer therapy." Biomedical Materials 17, no. 2 (January 24, 2022): 024103. http://dx.doi.org/10.1088/1748-605x/ac494c.
Повний текст джерелаIlca, F. Tudor, Andreas Neerincx, Mark R. Wills, Maike de la Roche, and Louise H. Boyle. "Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules." Proceedings of the National Academy of Sciences 115, no. 40 (September 13, 2018): E9353—E9361. http://dx.doi.org/10.1073/pnas.1809465115.
Повний текст джерелаSette, A., S. Southwood, J. Miller, and E. Appella. "Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II." Journal of Experimental Medicine 181, no. 2 (February 1, 1995): 677–83. http://dx.doi.org/10.1084/jem.181.2.677.
Повний текст джерелаBednarek, M. A., S. Y. Sauma, M. C. Gammon, G. Porter, S. Tamhankar, A. R. Williamson, and H. J. Zweerink. "The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2." Journal of Immunology 147, no. 12 (December 15, 1991): 4047–53. http://dx.doi.org/10.4049/jimmunol.147.12.4047.
Повний текст джерелаДисертації з теми "Peptide loading"
Gupta, Shashank. "Identification and characterization of peptide-like MHC-ligand exchange catalyst as immune response enhancer." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2009. http://dx.doi.org/10.18452/15904.
Повний текст джерелаMHC class II molecules present antigenic peptides on the cell surface for the surveillance by CD4+ T cells. To ensure that these ligands accurately reflect the content of the intracellular MHC loading compartment, a complex processing pathway has evolved that delivers only stable peptide/MHC complexes to the surface. As additional safeguard mechanism, MHC molecules quickly acquire a ‘non-receptive’ state once they have lost their ligand. This study shows that amino acid side chains of short peptides can bypass these safety mechanisms by triggering the reversible ligand-exchange. The catalytic activity of dipeptides such as Tyr-Arg (YR) is stereo-specific and could be enhanced by modifications addressing the conserved H-bond network near the P1 pocket of the MHC molecule. It enhanced both antigen-loading and ligand-release and strictly correlated with reported anchor preferences of P1, the specific target site for the catalytic side chain of the dipeptide. The effect was evident also in CD4+ T cell assays, where the allele-selective influence of the dipeptides translated into increased sensitivities of the antigen-specific immune response. The hypothesis that occupation of P1 prevents the ‘closure’ of the ‘empty’ peptide binding site into the ‘non-receptive’ state was further supported by molecular dynamic calculations. During antigen processing and presentation P1 may therefore function as important ‘sensor’ for peptide-load. Spectroscopic studies using ANS dye (8-aninilino-1-napthalenesulfonic acid) and intrinsic tryptophan fluorescence data, confirm the postulate by providing direct evidence for the conformational transitions. Moreover conformation specific antibodies previously described to be specific for ‘empty’ MHC could be shown to be a ‘probe’ for ‘receptive conformation’. As potent risk factors short peptides may be involved in the induction of autoimmune diseases. It could be shown here that they could enhance the loading of gluten derived antigen on celiac disease linked-HLA-DQ2 allele. At least in vitro the effect could enhance gluten specific CD4+ T cell response on T cell clones obtained from celiac disease patients. Thus, on one hand short peptides might work as ‘MHC loading enhancer’ (MLE) in the precipitation of inflammatory-‘autoimmune’ disorder, on the other hand they might be used as drug like vaccine ‘additive’ in various therapeutic settings.
Urban, Sabrina. "Die Rolle von Aminopeptidasen in der MHC Klasse I Antigenprozessierung des HLA-A2-restingierten HCMV pp 65 495-503 Epitops im Zusammenhang mit dem peptide-loading complex." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2009. http://dx.doi.org/10.18452/15996.
Повний текст джерелаThe ubiquitin proteasome system is responsible for the generation of the majority of MHC class I presented antigenic peptides. By cooperation with alternative proteolytic systems the diversity of MHC class I ligands is increased. In this context, especially during immune response, the role of aminopeptidases is barely characterised. In this project the effect of cytosolic and ER-resident aminopeptidases on processing of proteasomal generated peptides was investigated with regard to HCMV pp65495-503 epitope generation. Therefore, expression level of single aminopeptidases was down regulated by siRNA in pp65 expressing cells and the effect of down regulation on epitope presentation was analysed by activation of pp65495-503 specific CTLs. It could be demonstrated that TPPII, LAP, AP-B and POP have negative effects on pp65 epitope presentation. With AP-B and POP two additional cytosolic aminopeptidases with a functional role in epitope processing were identified. Other aminopeptidases, that have been characterised as part of the antigen processing machinery, namely TOP, BH and PSA, did not affect pp65 epitope generation. In contrast, trimming by ERAPI and ERAPII in the ER resulted in an efficient epitope presentation. For the first time, experimental evidence was provided that the two ER-resident peptidases interact with the MHC class I peptide-loading complex (PLC). The obtained results indicate that this association takes place independently of the assembly of the entire complex including TAP and is probably mediated by tapasin. The observation that this complex formation is inducible by IFNgamma suggests that the association of ERAPI and ERAPII to the PLC accounts for a better antigen processing and presentation mainly at the site of infection.
Du, Tingting. "Dissecting Small RNA Loading Pathway in Drosophila melanogaster: A Dissertation." eScholarship@UMMS, 2008. https://escholarship.umassmed.edu/gsbs_diss/356.
Повний текст джерелаChen, Yan. "Identification of new components of the MHC class I peptide loading complex." 2006. http://link.library.utoronto.ca/eir/EIRdetail.cfm?Resources__ID=450472&T=F.
Повний текст джерелаChu, Ya-Chun, and 朱雅郡. "Preparation of gelation nanocarrier with gp91 peptide loading for corneal neovascularization treatment." Thesis, 2017. http://ndltd.ncl.edu.tw/handle/d9bdhk.
Повний текст джерела國立臺北科技大學
生化與生醫工程研究所
105
Healthy cornea is a transparent, avascular tissue that allows light to pass through. The process of abnormal vessels growing into the cornea from limbus, is called corneal neovascularization (CNV). CNV may disturb the light go through the cornea, which can result in decreased vison or even blindness. Type 2 nicotinamide adenine dinucleotide phosphate-oxidase (Nox2) is the subunit of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase that plays a role in angiogenesis. A peptide called gp91-ds-tat (gp91) is a specific and effective inhibitor for Nox2. The gp91 peptide can decrease the generation of reactive oxygen species (ROS) and the expression of vascular endothelial growth factor (VEGF). Therefore, in this study, we selected gp91 peptide as the drug to inhibit the angiogenesis. Eye drops are the most common way to treat ocular diseases due to its low bioavailability on ocular surface resulted in unsatisfied therapeutic effect. Nowadays, nanomedicine as eyedrop can increase drug retain on eyes, then improve therapeutic effect drawing attention for eye disease treatment including CNV. In this study, we developed gelatin nanoparticles loaded with gp91 peptide (GNP-gp91) as a nanomedicine to inhibit angiogenesis in eyes. Firstly, GNP-gp91 nanoparticles were synthesized, and its particle size/zeta potential were exanimated. In vitro study, we co-culture the GNP-gp91 with the human umbilical vein endothelial cells (HUVEC) to evaluate the cell viability by WST-8 and live/dead staining methods. The inhibitory effect for HUVECs of GNP-gp91 was tested by cell migration, transwell cell migration, tube formation and ROS generation assays. In vivo test, we observed the retention of nanomedicine on ocular surfaces of mice by non invasion in vivo imaging system (IVIS). We established a mouse CNV model to evaluate the therapeutic effect of GNP-gp91 as eyedrop by every two days treatmen. In conclusion, we successfully prepared the GNP-gp91 in the size of 550.6 ± 61.2 nm, and the zeta potential of 21.7 ± 1.8 mV which is good for ocular drug delivery. The TEM images showed that these particles have spherical morphology. In the in vitro study, we found that GNP-gp91 was non-cytotoxicity and can significantly inhibit cell viability at the peptide concentration of 100 μg/mL. Cell migration demonstrated that GNP-gp91 was more effective for inhibiting HUVEC cells migration than the gp91 in solution at 6 and 8 hours. From the in vivo study, the retention time of GNP-gp91 on ocular surface is longer then solution form in normal cornea. We successfully established the CNV model and the therapeutic effect of GNP-gp91 is greater than gp91 in solution. And VEGF expression of total cornea lysis showed decreasing after ocular surface treatment with GNP-gp91. Overall, GNP-gp91 was produced in nano-size, and it can effectively inhibit the migration/tube formation of HUVEC at peptide concentration of 100 μg/mL. In vivo evaluation shows that mice treated with GNP-gp91 as eye drop had better anti-angiogenesis in corneal at day 7 after every-two days treatment. We believe that GNP-gp91 nanomedicine as eye drop has the potential to treat CNV as eye drop in an easy way in the future for clinical application.
Sever, Lital. "A Functional Study of the Major Histocompatibility Class I Antigen Presentation Pathway in Rainbow Trout (Oncorhynchus mykiss)." Thesis, 2014. http://hdl.handle.net/10012/8135.
Повний текст джерелаUrban, Sabrina [Verfasser]. "Die Rolle von Aminopeptidasen in der MHC-Klasse-I-Antigenprozessierung des HLA-A2-restingierten HCMV- pp65495-503-Epitops im Zusammenhang mit dem peptide-loading complex / von Sabrina Urban." 2009. http://d-nb.info/999433946/34.
Повний текст джерелаMácha, Hynek. "Vývoj metody pro stanovení loadingu aminokyselin při syntéze peptidů na pevné fázi." Master's thesis, 2018. http://www.nusl.cz/ntk/nusl-380289.
Повний текст джерелаHuang, Wei-Ting, and 黃唯婷. "Fabrication of Gold Nanoparticles-Based Platforms for Assaying Peptidase Activity and Loading Drugs." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/08854534097367288843.
Повний текст джерела國立交通大學
分子醫學與生物工程研究所
99
Gold nanoparticles (AuNPs) have received interests due to their characteristics, especially optical and physical properties. In this research, the optical biosensing and fluorescent platforms were developed. Both AuNPs-based biosensing platforms were set up based on the surface plasmon resonance (SPR) property of AuNPs to detect certain peptidase activity. Additionally, the surface-modified techniques of AuNPs were also utilized on the drug load and delivery. The AuNPs-based optical biosensing system was established by means of the varied SPR spectra of AuNPs, while AuNPs changed their sizes, included aggregation or modified with functional molecules. According to the mechanism, AuNPs modified with peptide (AuNP/peptide) that was used as a peptidase (matrix metalloprotease-2; MMP-2) substrate and also a shelter to protect AuNPs from aggregation. After MMP-2 digested, AuNPs became aggregation because of decreasing the steric repulsion among AuNPs. The aggregation of AuNPs was measured via the red-shift of SPR absorption. Therefore, the MMP-2 activity could be quantitatively estimated by the absorption ratio, A625 nm/A530 nm. The results show that the detection limit of the established platform was 100 ng/mL, a linear correlation between MMP-2 was ranging from 100 to 1,500 ng/mL, and the changes of A625 nm/A530 nm was observed (R2 = 0.9703). For improving the sensitivity of AuNPs-based platform, the peptide was exchanged with peptide-FITC as substrate modified on AuNPs to establish AuNPs-based fluorescence platform. The FITC would be quenched by AuNPs when the peptide-FITC modified on AuNPs surface. The fluorescence intensity of FITC was detected after MMP-2 digested the peptide leading peptide-FITC released from AuNPs surface. According to the concept, the MMP-2 activity could be analyzed by measuring the change of fluorescence intensity (at emission of FITC, 515 nm). The AuNPs-based fluorescence platform performed a detection limit as 0.01 ng/mL, with a linear correlation ranging from 0.01 to 2 ng/mL of MMP-2 (R2 = 0.9759). Additionally, both AuNPs-based optical and fluorescence platforms showed the ability to assay the efficiency of MMPs inhibitors with high specificity. Especially, the AuNPs-based fluorescence platform could apply in cellular peptidase activity analysis through bio-image (confocal) that revealed a promising potential to utilize in in vivo peptidase detection. On the other hand, the AuNPs-based delivery platform was fabricated due to the biocomplementary and various surface modifications of AuNPs through special molecules with their functional groups. Based on the concept, the AuNPs were conjugated with human growth hormone protein (hGH) used to target the hGH receptor of HepG2 cells, and Raman reporter (malachite green isothiocyanate; MGITC) as tags. After incubating the AuNPs-complexes with HepG2 cells, the AuNPs specifically targeted to the cells and could be traced in cells by surface-enhanced Raman scattering through Raman confocal. In addition, AuNPs were also used as drug delivery carrier by modifying AuNPs with hGH and anticancer drug, doxorubicin. Using AuNPs/hGH-doxorubicin could bind HepG2 cells precisely and inhibit the growth of cancer cells at the same time. This result indicates that the multifunctional AuNPs improved the effective of the medicine in vitro according to selective targeting and treating drug to the objective in once.
Jao, Chia-Ai, та 饒佳艾. "Association Between Periodontal Disease and Alzheimer’s Disease--From Amyloid-β Peptide Loading:A Systematic Review and Meta-Analysis". Thesis, 2019. http://ndltd.ncl.edu.tw/handle/fy67x8.
Повний текст джерелаКниги з теми "Peptide loading"
Yan, Chen. Identification of new components of the MHC class I peptide loading complex. 2006.
Знайти повний текст джерелаЧастини книг з теми "Peptide loading"
Kim, AeRyon, Isabel Emiko Ishizuka, Isamu Z. Hartman, Yuri Poluektov, Kedar Narayan, and Scheherazade Sadegh-Nasseri. "Studying MHC Class II Peptide Loading and Editing In Vitro." In Antigen Processing, 343–55. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9450-2_24.
Повний текст джерелаKim, AeRyon, Isabel Ishizuka, Isamu Hartman, Yuri Poluektov, Kedar Narayan, and Scheherazade Sadegh-Nasseri. "Studying MHC Class II Peptide Loading and Editing In Vitro." In Antigen Processing, 447–59. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-218-6_33.
Повний текст джерелаBouvier, Marlene. "Studying MHC Class I Peptide Loading and Exchange In vitro." In Antigen Processing, 81–91. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-218-6_7.
Повний текст джерелаBouvier, Marlene. "In Vitro Studies of MHC Class I Peptide Loading and Exchange." In Antigen Processing, 71–81. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9450-2_6.
Повний текст джерелаMargulies, David H., Jiansheng Jiang, and Kannan Natarajan. "Structure and Function of Molecular Chaperones that Govern Immune Peptide Loading." In Subcellular Biochemistry, 321–37. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-28151-9_10.
Повний текст джерелаWearsch, Pamela A., and Peter Cresswell. "In Vitro Reconstitution of the MHC Class I Peptide-Loading Complex." In Antigen Processing, 67–79. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-218-6_6.
Повний текст джерелаHou, Tieying, Cornelia Rinderknecht, Debopam Ghosh, Andreas V. Hadjinicolaou, Robert Busch, and Elizabeth D. Mellins. "Pulse–Chase Analysis for Studies of MHC Class II Biosynthesis, Maturation, and Peptide Loading." In Antigen Processing, 315–41. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9450-2_23.
Повний текст джерелаHou, Tieying, Cornelia H. Rinderknecht, Andreas V. Hadjinicolaou, Robert Busch, and Elizabeth Mellins. "Pulse–Chase Analysis for Studies of MHC Class II Biosynthesis, Maturation, and Peptide Loading." In Antigen Processing, 411–32. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-218-6_31.
Повний текст джерелаSambhi, M., M. Kohno, and K. Clegg. "Salt Loading in Spontaneously Hypertensive Rats Further Elevates Blood Pressure Despite Enhanced Release of Atrial Natriuretic Peptides and Exaggerated Natriuresis." In Diuretics: Basic, Pharmacological, and Clinical Aspects, 140–44. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-2067-8_34.
Повний текст джерелаCall, Melissa J. "Peptide Loading of MHC." In Handbook of Biologically Active Peptides, 687–96. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-12-385095-9.00093-2.
Повний текст джерелаТези доповідей конференцій з теми "Peptide loading"
Piehowski, Paul D., Yang Wang, James A. Sanford, Joshua R. Hansen, Marina A. Gritsenko, Vladislav A. Petyuk, Karl K. Weitz, et al. "Abstract 5125: Evaluation of differential peptide loading on TMT-based proteomic on phosphoproteomic data quality in an AML model." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5125.
Повний текст джерелаChen, Jing, and Sihong Wang. "Thermal Effects on Osteogenesis of Human Mesenchymal Stem Cells." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80885.
Повний текст джерелаKeten, Sinan, and Markus J. Buehler. "Elasticity and Strength of Beta-Sheet Protein Materials: Geometric Confinement and Size Effects." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-205464.
Повний текст джерелаDownie, LS, LM Work, and SA Nicklin. "10 Endogenous and exogenous loading of extracellular vesicles for therapeutic delivery of renin-angiotensin system peptides in cardiomyocyte hypertrophy." In The Scottish Cardiovascular Forum 2018, 3rd February 2018, Trinity Biomedical Science Institute, Trinity College Dublin Ireland. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-scf.10.
Повний текст джерела